tirzepatide surmount ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction Presented today at #ECO2026 ⤵️

Craig Primack, Hims & Hers SVP of Weight Management, joins 'Closing Bell Overtime' to talk the company offering a GLP-1 drug through its platform.

Semaglutide after gallbladder removal requires careful consideration of bile acid metabolism and gastrointestinal side effects

Mean body weight decreased by 8.24.9kg (7.3% 4.4%), with a BMI reduction of 2.81.7kg/m

It is not approved for any of these yet, but the intent is clearly broader metabolic health, not just weight loss

These results highlight significant heterogeneity in weight trajectories following sustained exposure to a GLP-1RA therapy and identifies factors associated with increased weight loss, likely reflecting a combination of biological, behavioral, and social factors

We will never send spam or annoying emails